VISIGALLI, DAVIDE
 Distribuzione geografica
Continente #
EU - Europa 1.827
Totale 1.827
Nazione #
IT - Italia 1.827
Totale 1.827
Città #
Genova 1.166
Rapallo 265
Genoa 248
Vado Ligure 146
Bordighera 2
Totale 1.827
Nome #
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies 146
The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A 145
Hind limb unloading of micemodulates gene expression at the protein and mRNA level in mesenchymal bonecells. 134
Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy 131
Alternative Splicing in the Human PMP22 Gene: Implications in CMT1A Neuropathy 119
The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts 116
Soluble Neuregulin1 is strongly up-regulated in the rat model of Charcot-Marie-Tooth 1A disease 116
Oxydative phosphorylation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 101
PMP22 messenger RNA levels in skin biopsies: Testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker 99
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 97
P2X7 antagonism in experimental CMT1A: a potential therapeutic strategy 95
Oxydative phosphorilation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 93
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 85
The diadenosine homodinucleotide P18 improvesin vitromyelination in experimental Charcot-Marie-Tooth type 1A 80
Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A 69
P2X7 RECEPTOR IMPLICATION IN CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 67
P2X7 TARGETING IMPROVES IN VITRO MYELINATION IN EXPERIMENTAL CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 63
null 48
Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome Following an Antecedent Parainfectious COVID-19-Related GBS 32
DEVELOPMENT AND VALIDATION OF A BIOMARKERS PANEL TO CAPTURE PATHOPHYSIOLOGICAL HETEROGENEITY OF GBS AND CIDP PATIENTS 22
COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome 11
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS 6
Monitoring Myelin Lipid Composition and the Structure of Myelinated Fibers Reveals a Maturation Delay in CMT1A 6
Totale 1.881
Categoria #
all - tutte 6.370
article - articoli 5.853
book - libri 0
conference - conferenze 517
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.740


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020340 0 0 0 0 27 46 69 36 37 75 40 10
2020/2021106 5 11 5 21 6 7 6 11 11 10 8 5
2021/2022239 12 9 18 24 4 17 9 66 16 18 6 40
2022/2023302 22 34 2 23 53 40 4 27 52 0 43 2
2023/2024194 6 20 7 26 17 32 28 5 7 7 6 33
2024/2025178 51 32 19 38 38 0 0 0 0 0 0 0
Totale 1.881